Magle Chemoswed Holding AB (52X) AI Stock Analysis

0 Followers

Magle Chemoswed Holding AB

(Frankfurt:52X)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthPositive TTM revenue growth indicates that customer demand for the company’s development and manufacturing services is expanding. If maintained, this broader revenue base can support better operating leverage and provide a foundation for rebuilding profitability over the next several quarters.

Negative Factors

Severe Profitability DeteriorationThe sharp move to a deeply negative net margin shows that current operating costs are overwhelming gross profit despite revenue growth. Persistent losses could limit internal reinvestment, weaken financial resilience, and make a durable earnings recovery dependent on substantial cost improvement.

Magle Chemoswed Holding AB (52X) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.55M
Dividend Yield: ―
Average Volume (3M): 280
Price to Earnings (P/E): -0.0
Beta (1Y): 0.34
Revenue Growth: 5.48%
EPS Growth: -1289.32%
Country: Germany
Employees: 150
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Magle Chemoswed Holding AB Business Overview & Revenue Model

Company Description

Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process developme...

Magle Chemoswed Holding AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:52X against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	83Outperform	SEK 403.18M	2.06	63.09%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ELIC	47Neutral	SEK 173.18M	-7.35	-56.09%	―	―	14.10%
SE:BINV	43Neutral	SEK 198.73M	-0.39	-128.54%	―	-83.67%	-50.29%
SE:SPAGO	43Neutral	SEK 37.36M	-1.13	-87.37%	―	-97.52%	31.31%
SE:NEEMS.B	38Underperform	SEK 54.00M	-14.45	-190.99%	―	3.73%	16.13%

* Healthcare Sector Average

Performance Comparison

DE:52X and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:52X	Magle Chemoswed Holding AB	0.02	-1.66	-98.75%
SE:BINV	BioInvent International AB	2.92	-27.23	-90.32%
SE:NEEMS.B	Scandinavian ChemoTech AB Class B	2.09	-2.21	-51.40%
SE:ELIC	Elicera Therapeutics AB	2.60	-2.77	-51.56%
SE:SPAGO	Spago Nanomedical AB	0.04	-0.07	-59.82%
SE:CANTA	Cantargia AB	1.40	-2.19	-60.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Magle Chemoswed Holding AB AI Stock Analysis